LFF-571

LFF-571 is a novel semisynthetic thiopeptide antibiotic developed for the treatment of *Clostridium difficile* infection. It exhibits potent *in vitro* activity against a variety of Gram-positive pathogens, particularly *C. difficile*, and has demonstrated greater potency than vancomycin and metronidazole in laboratory studies. The drug acts by inhibiting bacterial protein synthesis through binding to elongation factor Tu (EF-Tu), thereby blocking the delivery of aminoacylated tRNA to the ribosome and halting translation. Clinical trials have shown that oral LFF-571 is generally safe and well tolerated, with limited systemic absorption and high fecal concentrations—making it suitable for gastrointestinal infections like *C. difficile*. Development was led by Novartis, with phase 2 clinical trials completed for moderate *C. difficile* infection.

Other names

J3.333.591AJ-3.333.591AJ 3.333.591A